Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients
Mao Z., Baker JR., Takeuchi M., Hyogo H., Tjønneland A., Eriksen AK., Severi G., Rothwell J., Laouali N., Katzke V., Kaaks R., Schulze MB., Palli D., Sieri S., de Magistris MS., Tumino R., Sacerdote C., Derksen JWG., Gram IT., Skeie G., Sandanger TM., Quirós JR., Crous-Bou M., Sánchez MJ., Amiano P., Colorado-Yohar SM., Guevara M., Harlid S., Johansson I., Perez-Cornago A., Freisling H., Gunter M., Weiderpass E., Heath AK., Aglago E., Jenab M., Fedirko V.
Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend